Sponsor pipeline

Novartis Pharmaceuticals clinical trial pipeline

Get alerts when Novartis Pharmaceuticals's trials change

371 active trials 188 recruiting 93 Phase 3 59 disease areas 89 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days showing 43 of 89 changes on 20 trials

2026-10-06
Primary completion pushed from Aug 2, 2028 to Jan 29, 2029
Enrollment increased: 104 → 140 participants
Completion pushed from Sep 30, 2030 to Jun 18, 2031
NCT06997588 EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics… · Phase 2
2026-10-03
Primary completion pushed from Feb 22, 2036 to Apr 18, 2039
Enrollment reduced: 1400 → 1105 participants
Completion pushed from Feb 22, 2036 to Apr 18, 2039
NCT02445222 CAR-T Long Term Follow Up (LTFU) Study · Phase 3
2026-10-02
Primary completion pushed from Apr 8, 2030 to Apr 3, 2034
Trial sites expanded: 143 → 162 locations
Completion pushed from Apr 5, 2032 to Oct 2, 2034
NCT06133972 Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With… · Phase 3
2026-09-19
Primary completion pushed from May 9, 2028 to Jan 18, 2029
NCT07421167 A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice… · Phase 2
2026-09-19
Primary completion pushed from Jun 27, 2031 to Mar 23, 2032
Completion pushed from Jul 25, 2031 to Apr 20, 2032
NCT07679269 Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. · Phase 2
2026-09-30
Primary endpoint(s) modified
Interventions modified
NCT07190300 TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With… · Phase 1/2
2026-10-08
Enrollment closed, study ongoing
Final enrollment: 246 participants (planned 340)
NCT06813911 Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants… · Phase 3
2026-10-06
Enrollment reopened
Enrollment increased: 448 → 540 participants
Trial sites expanded: 155 → 161 locations
NCT04557462 A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of… · Phase 3
2026-10-07
Enrollment closed, study ongoing
Final enrollment: 25 participants (planned 40)
NCT07468071 Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit… · Phase 1/2
2026-10-03
Recruitment opened
Primary completion moved earlier from Jul 17, 2028 to Jun 2, 2028
Completion moved earlier from Jul 17, 2028 to Jun 2, 2028
Start date changed from estimate of Nov 9, 2026 to Sep 21, 2026
NCT07816328 Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult… · Phase 3
2026-09-29
Enrollment closed, study ongoing
Trial sites reduced: 130 → 120 locations
NCT06744920 A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus… · Phase 3
2026-10-10
Primary completion pushed from Feb 13, 2032 to Mar 15, 2032
Completion pushed from Sep 4, 2035 to Oct 4, 2035
NCT06991556 An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult… · Phase 2
2026-09-30
Recruitment opened
Trial sites expanded: 0 → 3 locations
NCT07748624 A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants… · Phase 2
2026-09-29
Trial completed
NCT05798117 An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in… · Phase 1/2
2026-09-25
Recruitment opened
Primary completion pushed from Sep 16, 2027 to Oct 19, 2027
Completion pushed from Sep 16, 2027 to Oct 19, 2027
Start date changed from estimate of Nov 9, 2026 to Sep 18, 2026
NCT07830719 Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With… · Phase 2
2026-09-19
Recruitment opened
NCT07448610 ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants… · Phase 4
2026-09-18
Recruitment opened
NCT07801495 A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With… · Phase 2
2026-09-30
Recruitment opened
Start date changed from estimate of Sep 21, 2026 to Sep 22, 2026
NCT07598448 A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an…
2026-09-23
Recruitment opened
NCT07783503 A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the… · Phase 1
2026-09-25
Enrollment closed, study ongoing
Final enrollment: 670 participants (planned 600)
NCT05217810 A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world…

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-09 NCT07868328 A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary… Phase 2 Not Yet Recruiting
2026-10-02 NCT07855276 A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to… Phase 1 Not Yet Recruiting
2026-09-30 NCT07850752 A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With… Phase 3 Not Yet Recruiting
2026-09-28 NCT07843758 An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant… Completed
2026-09-28 NCT07844070 A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During… Active, Not Recruiting
2026-09-24 NCT07839858 A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment… Completed
2026-09-21 NCT07830719 Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With… Phase 2 Recruiting
2026-09-15 NCT07821411 A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan Active, Not Recruiting
2026-09-11 NCT07816328 Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult… Phase 3 Recruiting

Active trials by phase

Phase 1
43
Phase 1/2
26
Phase 2
71
Phase 2/3
2
Phase 3
91
Phase 4
25
Not charted: 113 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 371

NCT IDTitleConditionStatusUpdated
Phase 4
NCT03340506 Dabrafenib and/or Trametinib Rollover Study Melanoma Recruiting 2026-10-09
NCT04638647 Secukinumab Open Label Roll-over Extension Protocol Autoimmunity, Inflammation Recruiting 2026-09-28
NCT07448610 ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants… Spinal Muscular Atrophy Recruiting 2026-09-18
NCT07489573 Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to… Hidradenitis Suppurativa (HS) Recruiting 2026-09-09
NCT04877522 Asciminib Roll-over Study Chronic Myelogenous Leukemia Recruiting 2026-07-06
NCT04480853 Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing… Multiple Sclerosis Recruiting 2026-06-26
NCT04657822 Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior… Sickle Cell Disease Recruiting 2026-06-08
NCT06824103 Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With… Graft vs. Host Disease Recruiting 2026-06-08
NCT05803941 Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate… Prostate Cancer Recruiting 2026-06-04
NCT06733922 ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS Relapsing Remitting Multiple Sclerosis (RRMS) Recruiting 2026-05-15
NCT07034690 Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in… Atherosclerotic Cardiovascular Disease Recruiting 2026-05-04
NCT06501443 LATAM LOWERS LDL-C Hypercholesterolaemia Recruiting 2025-12-30
NCT05161195 Roll-over Study to Allow Continued Access to Ribociclib Metastatic Breast Cancer Active, Not Recruiting 2026-10-09
NCT02584933 Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib… ALK Positive Malignancies Active, Not Recruiting 2026-09-17
NCT05252585 A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous… Renal Angiomyolipoma Active, Not Recruiting 2026-09-17
NCT06462469 Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV… Steroid-refractory Acute Graft Versus Host Disease Active, Not Recruiting 2026-09-17
NCT03975829 Pediatric Long-Term Follow-up and Rollover Study Diffuse Astrocytoma Active, Not Recruiting 2026-08-27
NCT05622708 A Study of Secukinumab to Evaluate Maintenance of Response in Participants With… Non-radiographic Axial Spondyloarthritis Active, Not Recruiting 2026-08-21
NCT02386800 CINC424A2X01B Rollover Protocol Primary Myelofibrosis Active, Not Recruiting 2026-08-20
NCT06444113 Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of… Multiple Sclerosis Active, Not Recruiting 2026-08-12
NCT06372925 Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute… Plaque, Atherosclerotic Active, Not Recruiting 2026-07-28
NCT07713602 Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in… Malaria Not Yet Recruiting 2026-07-20
NCT07684469 Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care… Acute Coronary Syndrome Not Yet Recruiting 2026-07-06
NCT05090371 A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After… Relapsing-Remitting Multiple Sclerosis Active, Not Recruiting 2026-05-29
NCT06941792 Inclisiran Effectiveness in China: a Pragmatic Randomized Trial Coronary Heart Disease Active, Not Recruiting 2026-05-29
See all 371 active Novartis Pharmaceuticals trials with filters →

Disease areas by active trials, top 10 of 59

Breast Cancer (33) · Prostate Cancer (32) · Multiple Sclerosis (27) · Leukemia (25) · Lung Cancer (19) · Non-Small Cell Lung Cancer (NSCLC) (17) · Hidradenitis Suppurativa (16) · Chronic Myeloid Leukemia (CML) (14) · Heart Disease (10) · Lupus (SLE) (9)

Get alerts when Novartis Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free